XTL Biopharmaceuticals Ltd (XTLB) — Cash Flow-to-Debt Ratio
XTL Biopharmaceuticals Ltd (XTLB) has a Cash Flow-to-Debt Ratio of -0.10x as of December 2017, meaning its operating cash flow of ILA-301.00K could theoretically repay 0% of its total liabilities (ILA2.97 Million) in one year. See XTL Biopharmaceuticals Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
XTL Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for XTL Biopharmaceuticals Ltd across 12 annual periods. For the full cash flow conversion analysis, see XTL Biopharmaceuticals Ltd cash flow conversion.
Annual Cash Flow-to-Debt Ratio for XTL Biopharmaceuticals Ltd (2013–2024)
Year-by-year debt coverage analysis for XTL Biopharmaceuticals Ltd. Check XTL Biopharmaceuticals Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | ILA-1.62 Million | ILA3.12 Million | ▲ +84.9% |
| 2023 | -3.43x | ILA-707.00K | ILA206.00K | ▲ +28.8% |
| 2022 | -4.82x | ILA-901.00K | ILA187.00K | ▼ -490.2% |
| 2021 | -0.82x | ILA-1.05 Million | ILA1.28 Million | ▲ +75.6% |
| 2020 | -3.35x | ILA-850.00K | ILA254.00K | ▲ +14.5% |
| 2019 | -3.91x | ILA-908.00K | ILA232.00K | ▼ -21.3% |
| 2018 | -3.23x | ILA-816.00K | ILA253.00K | ▼ -750.6% |
| 2017 | -0.38x | ILA-1.12 Million | ILA2.97 Million | ▲ +92.8% |
| 2016 | -5.25x | ILA-1.73 Million | ILA330.00K | ▼ -23.0% |
| 2015 | -4.27x | ILA-1.86 Million | ILA436.00K | ▼ -66.8% |
| 2014 | -2.56x | ILA-2.47 Million | ILA965.00K | ▼ -26.0% |
| 2013 | -2.03x | ILA-2.50 Million | ILA1.23 Million | — |